IL124454A - Injectable danofloxacin formulations - Google Patents

Injectable danofloxacin formulations

Info

Publication number
IL124454A
IL124454A IL12445496A IL12445496A IL124454A IL 124454 A IL124454 A IL 124454A IL 12445496 A IL12445496 A IL 12445496A IL 12445496 A IL12445496 A IL 12445496A IL 124454 A IL124454 A IL 124454A
Authority
IL
Israel
Prior art keywords
danofloxacin
injectable
formulations
injectable danofloxacin
danofloxacin formulations
Prior art date
Application number
IL12445496A
Other languages
English (en)
Other versions
IL124454A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21735307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL124454(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of IL124454A0 publication Critical patent/IL124454A0/xx
Publication of IL124454A publication Critical patent/IL124454A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995Pyrazines or piperazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL12445496A 1995-12-21 1996-11-13 Injectable danofloxacin formulations IL124454A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US905295P 1995-12-21 1995-12-21
PCT/IB1996/001217 WO1997023217A1 (en) 1995-12-21 1996-11-13 Injectable quinolone formulations

Publications (2)

Publication Number Publication Date
IL124454A0 IL124454A0 (en) 1998-12-06
IL124454A true IL124454A (en) 2003-10-31

Family

ID=21735307

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12445496A IL124454A (en) 1995-12-21 1996-11-13 Injectable danofloxacin formulations

Country Status (42)

Country Link
US (1) US5811130A (ja)
EP (1) EP0868183B1 (ja)
JP (1) JP3416145B2 (ja)
KR (1) KR100402570B1 (ja)
CN (1) CN1104899C (ja)
AP (1) AP706A (ja)
AR (1) AR005147A1 (ja)
AT (1) ATE212551T1 (ja)
AU (1) AU709474B2 (ja)
BG (1) BG63933B1 (ja)
BR (1) BR9612230A (ja)
CA (1) CA2239352C (ja)
CO (1) CO4480098A1 (ja)
CZ (1) CZ293747B6 (ja)
DE (1) DE69618987T2 (ja)
DK (1) DK0868183T3 (ja)
DZ (1) DZ2146A1 (ja)
EG (1) EG24071A (ja)
ES (1) ES2167609T3 (ja)
GT (1) GT199600098A (ja)
HR (1) HRP960607B1 (ja)
HU (1) HU227918B1 (ja)
IL (1) IL124454A (ja)
IS (1) IS2010B (ja)
MA (1) MA24035A1 (ja)
MX (1) MX9805026A (ja)
MY (1) MY117109A (ja)
NO (1) NO315734B1 (ja)
NZ (2) NZ320545A (ja)
OA (1) OA10697A (ja)
PE (1) PE25798A1 (ja)
PL (1) PL186795B1 (ja)
PT (1) PT868183E (ja)
RS (1) RS49523B (ja)
RU (1) RU2141827C1 (ja)
SI (1) SI0868183T1 (ja)
SK (1) SK284412B6 (ja)
TN (1) TNSN96163A1 (ja)
TW (1) TW449475B (ja)
UA (1) UA56151C2 (ja)
WO (1) WO1997023217A1 (ja)
ZA (1) ZA9610780B (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID21415A (id) * 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
DE19937116A1 (de) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
AU2001228454A1 (en) * 2000-01-13 2001-07-24 Merck Patent G.M.B.H Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary
EP1356809A4 (en) * 2000-12-28 2008-05-14 Takeda Pharmaceutical SUSTAINED RELEASE PREPARATIONS
CA2488526A1 (en) * 2002-06-26 2004-01-08 Pharmacia Corporation Stable liquid parenteral parecoxib formulation
US20090117205A1 (en) * 2004-07-02 2009-05-07 Daiichi Pharmaceutical Co., Ltd Quinolone-containing medicinal composition
PT2594272T (pt) * 2005-05-18 2018-07-31 Horizon Orphan Llc Fluoroquinolonas aerossolizadas e suas utilizações
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
FR2896416B1 (fr) 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
WO2007090646A1 (en) * 2006-02-10 2007-08-16 Pari Pharma Gmbh Nebulised antibiotics for inhalation therapy
US20070197548A1 (en) 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
MX2007009796A (es) * 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
HUE038428T2 (hu) 2008-10-07 2018-10-29 Horizon Orphan Llc Aeroszol fluorokinolon készítmények javított farmakokinetika érdekében
SI2346509T1 (sl) 2008-10-07 2020-08-31 Horizon Orphan Llc Inhalacija levofloksacina za zmanjšanje vnetja pljuč
BR112012004692B8 (pt) 2009-09-04 2021-05-25 Mpex Pharmaceuticals Inc solução que compreende levofloxacina para uso em um método para tratar a fibrose cística em um ser humano
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
EP3305296A4 (en) 2015-06-02 2019-02-13 Kyorin Pharmaceutical Co., Ltd. AQUEOUS LIQUID FORMULATION
EP3305295A4 (en) 2015-06-02 2019-02-20 Kyorin Pharmaceutical Co., Ltd. AQUEOUS MEDICINE
WO2016195014A1 (ja) 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
AU2018217931B2 (en) * 2017-02-13 2023-04-13 Elanco Animal Health Gmbh Liquid composition containing pradofloxacin
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3517709A1 (de) * 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
JPS63188626A (ja) * 1987-01-30 1988-08-04 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸の可溶化方法
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
ES2102393T3 (es) * 1989-12-29 1997-08-01 Abbott Lab Complejos de acido quinolona carboxilico--ion metalico--acido.
US5084276A (en) * 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
ATE108649T1 (de) * 1990-02-14 1994-08-15 Takeda Chemical Industries Ltd Brausemischung, deren herstellung sowie verwendung.
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
US5235054A (en) * 1992-07-15 1993-08-10 Pfizer Inc. 3-carboxaldehyde substituted quinolines and naphthyridines
JPH0782141A (ja) * 1993-09-17 1995-03-28 Tanabe Seiyaku Co Ltd 動物用注射剤

Also Published As

Publication number Publication date
HRP960607B1 (en) 2002-06-30
BG102542A (en) 1999-06-30
HRP960607A2 (en) 1998-06-30
HUP9903726A2 (hu) 2000-04-28
HU227918B1 (en) 2012-06-28
CN1205636A (zh) 1999-01-20
BG63933B1 (bg) 2003-07-31
RU2141827C1 (ru) 1999-11-27
TNSN96163A1 (fr) 2005-03-15
CZ193098A3 (cs) 1999-05-12
PE25798A1 (es) 1998-05-21
MA24035A1 (fr) 1997-07-01
BR9612230A (pt) 1999-07-13
IL124454A0 (en) 1998-12-06
YU69096A (sh) 1999-06-15
CO4480098A1 (es) 1997-07-09
SK80798A3 (en) 1999-09-10
SI0868183T1 (en) 2002-04-30
KR19990076617A (ko) 1999-10-15
DZ2146A1 (fr) 2002-10-23
PT868183E (pt) 2002-06-28
JPH11501331A (ja) 1999-02-02
NO315734B1 (no) 2003-10-20
IS4755A (is) 1998-05-25
SK284412B6 (sk) 2005-03-04
TW449475B (en) 2001-08-11
AU7328996A (en) 1997-07-17
NO982842D0 (no) 1998-06-19
ATE212551T1 (de) 2002-02-15
EP0868183A1 (en) 1998-10-07
RS49523B (sr) 2006-10-27
CN1104899C (zh) 2003-04-09
CA2239352A1 (en) 1997-07-03
OA10697A (en) 2001-05-04
DE69618987T2 (de) 2002-11-21
CA2239352C (en) 2002-06-04
NO982842L (no) 1998-06-19
DE69618987D1 (de) 2002-03-14
PL186795B1 (pl) 2004-02-27
DK0868183T3 (da) 2002-03-25
MX9805026A (es) 1998-09-30
JP3416145B2 (ja) 2003-06-16
NZ320545A (en) 2000-03-27
CZ293747B6 (cs) 2004-07-14
AP706A (en) 1998-12-04
AU709474B2 (en) 1999-08-26
PL328001A1 (en) 1999-01-04
MY117109A (en) 2004-05-31
EP0868183B1 (en) 2002-01-30
EG24071A (en) 2008-05-11
US5811130A (en) 1998-09-22
ZA9610780B (en) 1998-06-22
ES2167609T3 (es) 2002-05-16
IS2010B (is) 2005-05-13
AP9600898A0 (en) 1997-01-31
KR100402570B1 (ko) 2003-12-18
HUP9903726A3 (en) 2001-01-29
NZ501160A (en) 2001-10-26
AR005147A1 (es) 1999-04-14
UA56151C2 (uk) 2003-05-15
WO1997023217A1 (en) 1997-07-03
GT199600098A (es) 1998-06-12

Similar Documents

Publication Publication Date Title
IL124454A (en) Injectable danofloxacin formulations
GB2326093B (en) Avermectin formulation
IL127920A (en) Syringes
GB9513261D0 (en) Vaccines
GB2308302B (en) Syringe
GB2315414B (en) Syringes
GB9509291D0 (en) Formulations
GB9524722D0 (en) Syringes
GB9418550D0 (en) Drug formulation
HU9602732D0 (en) Lanperisone formulation
CA77371S (en) Ampoule
GB9524151D0 (en) Syringes
GB9513871D0 (en) Syringe
IL114370A0 (en) Syringe
GB9524458D0 (en) Syringe
GB9511410D0 (en) Syringe
GB9614326D0 (en) Medicament
GB9607355D0 (en) Syringes
GB9508144D0 (en) Formulations
GB9510349D0 (en) Formulations
GB9509941D0 (en) Formulations
GB9513443D0 (en) Vaccines
ZA962036B (en) Vaccines
GB9514088D0 (en) Vaccines
GB9508326D0 (en) Vaccines

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees